Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 9(4): e93672, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24705369

RESUMO

ApoER2 is a member of the low density-lipoprotein receptor (LDL-R) family. As a receptor for reelin, ApoER2 participates in neuronal migration during development as well as synaptic plasticity and survival in the adult brain. A previous yeast two-hybrid screen showed that ApoER2 is a binding partner of sorting nexin 17 (SNX17) - a cytosolic adaptor protein that regulates the trafficking of several membrane proteins in the endosomal pathway, including LRP1, P-selectin and integrins. However, no further studies have been performed to investigate the role of SNX17 in ApoER2 trafficking and function. In this study, we present evidence based on GST pull-down and inmunoprecipitation assays that the cytoplasmic NPxY endocytosis motif of ApoER2 interacts with the FERM domain of SNX17. SNX17 stimulates ApoER2 recycling in different cell lines including neurons without affecting its endocytic rate and also facilitates the transport of ApoER2 from the early endosomes to the recycling endosomes. The reduction of SNX17 was associated with accumulation of an ApoER2 carboxy-terminal fragment (CTF). In addition, in SNX17 knockdown cells, constitutive ApoER2 degradation was not modified, whereas reelin-induced ApoER2 degradation was increased, implying that SNX17 is a regulator of the receptor's half-life. Finally, in SNX17 silenced hippocampal and cortical neurons, we underscored a positive role of this endosomal protein in the development of the dendritic tree and reelin signaling. Overall, these results establish the role of SNX17 in ApoER2 trafficking and function and aid in identifying new links between endocytic trafficking and receptor signaling.


Assuntos
Moléculas de Adesão Celular Neuronais/metabolismo , Proteínas da Matriz Extracelular/metabolismo , Proteínas Relacionadas a Receptor de LDL/metabolismo , Proteínas do Tecido Nervoso/metabolismo , Serina Endopeptidases/metabolismo , Transdução de Sinais/fisiologia , Nexinas de Classificação/metabolismo , Secretases da Proteína Precursora do Amiloide/metabolismo , Animais , Escherichia coli , Citometria de Fluxo , Células HEK293 , Células HeLa , Humanos , Imunoprecipitação , Lentivirus , Neurônios/metabolismo , Ratos , Proteína Reelina
2.
Atherosclerosis ; 217(2): 299-307, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21741044

RESUMO

High-density lipoproteins (HDLs) are major carriers of cholesterol in the bloodstream and are critical in regulating cholesterol homeostasis in vivo. The first molecularly well-defined and physiologically relevant HDL receptor to be characterized was the scavenger receptor class B type I (SR-BI), a cell surface glycoprotein most highly expressed in liver and steroidogenic tissues. The HDL receptor SR-BI plays a key role in mediating selective HDL cholesterol (HDL-C) uptake in the liver, thus controlling cholesterol levels in plasma and the transhepatic traffic of this lipid into bile. SR-BI knockout mice exhibit increased plasma HDL-C levels and abnormally large HDL particles as well as reduced biliary cholesterol levels. Conversely, transgenic mice overexpressing SR-BI in the liver have markedly reduced plasma HDL levels, accelerated HDL-C clearance, increased hepatic selective cholesterol uptake, and raised biliary cholesterol content. The regulation of HDL-C metabolism by hepatic SR-BI is relevant for cardiovascular health as shown in mouse models where the lack of this receptor in the liver induces atherosclerotic lesions, whereas hepatic SR-BI overexpression entails a reduction of atherosclerosis. This review summarizes some recent progress in understanding the mechanisms that regulate hepatic SR-BI expression at transcriptional and post-transcriptional levels, providing opportunities for novel approaches that may improve HDL-dependent cholesterol homeostasis and lead to better prevention and treatment of atherosclerosis in humans.


Assuntos
Antígenos CD36/metabolismo , Lipoproteínas HDL/metabolismo , Fígado/metabolismo , Animais , Aterosclerose/metabolismo , Antígenos CD36/genética , HDL-Colesterol/metabolismo , Regulação da Expressão Gênica , Homeostase , Humanos , Processamento de Proteína Pós-Traducional , Transcrição Gênica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA